Teva Pharmaceutical Industries' share price tumbles after release of 2025 guidance, but analysts remain positive due to investment in innovative pipeline and debt reduction.
image sourced from original article at https://en.globes.co.il/en/article-analysts-remain-positive-on-teva-1001501006Original article source: https://en.globes.co.il/en/article-analysts-remain-positive-on-teva-1001501006
Source Id: 8528501304
